Loading...
First Round of Abstract Submission Ends: Aug 30, 2026
Extended Early Bird Ends: Jan 30, 2026

Keynote Speakers

Prof. Jian Wan
Central China Normal University, China
Title: To be Confirmed
Prof. Dr. Jian Wan, Guizi Scholar Distinguished Professor of Central China Normal University (CCNU), selected for the National High-level Talent Special Support Plan of PRC, the new century outstanding talent of MOE of PRC, former Dean of the Undergraduate School of CCNU.

Mainly engaged in the development and application of state of the art molecular modelling methods, combined with molecular biology, characterization analysis, and organic synthesis etc. techniques to study structure, function and regulation of the novel target protein and ligand complexes.
Dr. Motiur Rahman
King Saud University, Saudi Arabia
Title: Emerging Insights into Hydrazide-Hydrazone as anticancer Agents
Dr. Motiur Rahman is a distinguished researcher and scholar in the field of organic medicinal chemistry. Born in Rangpur, Bangladesh, in 1977, he holds a BSc (Honors) in Chemistry and an MSc in Organic Chemistry from the University of Rajshahi, Bangladesh. Driven by a passion for scientific inquiry, Dr. Rahman earned his PhD in Pharmaceutical Science from the College of Pharmacy at Yeungnam University, Korea. He completed his postdoctoral training at esteemed institutions such as Yeungnam University, Kyungpook National University, and UiTM Malaysia before joining the College of Pharmacy at King Saud University in 2010 as an Assistant Professor, where he currently serves as a Professor of Medicinal Chemistry. His research interests encompass a diverse range of topics, including the synthesis and biological activities of natural and synthetic molecules, total synthesis, methodology development for organic reactions, bio-conjugate chemistry, host-guest chemistry, and heterocyclic chemistry, with recent work focusing on drug metabolism. Dr. Rahman's research has been published in leading journals, including ACS Omega, Scientific Reports, Journal of Medical Chemistry, BMC, European Journal of Medicinal Chemistry, European Journal of Organic Chemistry, Tetrahedron, and Molecules. His dedication and expertise have notably advanced the field of organic medicinal chemistry.
Prof. Xuefeng Jiang
East China Normal University, China
Title: 3S Sulfur Chemistry
Professor Xuefeng Jiang, Shanghai Institute of Organic Chemistry, China（Ph.D., Prof. Shengming Ma, 2008), The Scripps Research Institute, US (Postdoc, 2008-2011, Prof. K. C. Nicolaou), Professor (East China Normal University, since 2011). His research interests involve Sulfur Chemistry, and AI for Synthesis. He is an esteemed member of the Chinese Chemical Society and the Royal Society of Chemistry, National Outstanding Youth. His notable awards comprisethe National Innovation Award (2023), the Shanghai Natural Science Award (First Class, 2024), the Shanghai Outstanding Youth Scientific and Technological Contribution Award (2023), and the CCS Youth Chemistry Award (2024), CAPA Distinguished Faculty Award (2020), Rising Stars Lectureship Award (2019), Thieme Chemistry Journal Award (Germany), ACP Lectureship Award (Japan). In recognition of his significant contributions to sulfur chemistry, he was selected as the IUPAC element ambassador for sulfur in the Periodic Table of Younger Chemists (2018).
Dr. Sveva Pelliccia
University of Naples Federico II, Italy
Title: Green and sustainable syntheses of pharmaceutically relevant compounds
Sveva Pelliccia received her PhD in Pharmaceutical Sciences at the Department of Pharmacy, University of Naples Federico II in 2013. From 2012 to 2016, she worked as a visiting PhD student and after as a postdoctoral fellow at “Sapienza”, University of Rome, under the supervision of Prof. Romano Silvestri. From April 2017 to May 2021 she held post-doctoral fellowships at University of Naples Federico II. Since December 2021, she became Assistant Professor at the Department of Pharmacy of the University of Naples Federico II. She was visiting scientist in the laboratories of Prof. R.C. Hider (King’s College, London) and Prof. E. Proschak (Goethe University, Frankfurt).

In 2023, Sveva received the “Finanziamento della Ricerca di Ateneo 2022 (FRA2022)” research grant from University of Naples Federico II and obtained the National Scientific Qualification (ASN) as Associate Professor in the disciplinary sector 03/D1 (CHEM07/A).

Sveva research interests range from the discovery of novel multicomponent reactions to the identification of novel anticancer and anti-infective agents in a green/sustainable declination.
Prof. Mehmet Polat
İzmir Institute of Technology, Turkey
Title: Physicochemical Aspects of Pre-Cellular Interactions of Nanocarriers in Physiological Environments: Implications for Cell Uptake
Mehmet Polat is a Professor of Chemical Engineering and currently is the Dean of the Faculty of Engineering at İzmir Institute of Technology, Turkey. He received his MSc and PhD degrees in Mineral Processing from Pennsylvania State University and has over thirty years of academic and research experience in nanoparticle synthesis, advanced characterization, and colloidal stability. His research focuses on organic (biopolymer) and inorganic (metal oxide) nanoparticles, sol–gel and Stöber-type synthesis routes, nucleation and growth mechanisms, surface charge regulation, and DLVO-based interaction forces governing dispersion stability in complex media.

Prof. Polat has extensive international research experience, including long-term appointments as Visiting Researcher at Advanced Institute of Science and Technology (AIST, Japan) and Chemistry Department at Ben-Gurion University (Israel). He has authored over 100 peer reviewed full papers in leading journals and conferences related to colloid and interface science and nanotechnology.

His recent work focuses on bridging nanoparticle engineering with biomedical and drug delivery applications, with particular emphasis on stability challenges in physiological environments, a topic of high relevance to both fundamental researchers and applied scientists in pharmaceutical sciences.
Prof. Wei-Shuo Fang
Institute of Materia Medica, CAS, China
Title: Probing new approach to modulate microtubule-tau PPI
Weishuo Fang graduated from Peking Union Medical College and awarded Ph.D. degree in 1997. After two years' postdoctoral study in Florida State University, USA, he started an independent career in Institute of Materia Medica, Chinese Academy of Medical Sciences and was promoted to full professor since then. The major theme of his research lab is medicinal chemistry and chemical biology of bioactive natural products. He has mentored more than 50 graduates and undergraduates, published more than 110 papers in peer reviewed journals and several books and book chapters. He is currently Associate Editors for Frontiers in Pharmacology and Frontiers in Chemistry, and Academic Editor for PLOS ONE. He was recognized as the 100th Excellent Doctoral Degree Dissertation Award in China (1999), the 1st SciTech Progress Prize recipient from Ministry of Health, China (1997), the recipient of CPA-Servier Young Investigator Awards in Medicinal Chemistry (2004), and the 2nd Science Research Achievement Prize recipient from Ministry of Education, China (2014).
Prof. Michael Oellerich
George-August University, Germany
Title: Donor-derived cell-free DNA for personalized immunosuppression in transplantation
Michael Oellerich, MD, HonMD, FADLM, FAMM, FFPath (RCPI), FRCPath, is a chemical pathologist and Distinguished Research Professor at the Department of Clinical Pharmacology, Medical Faculty (UMG), George-August University, Göttingen, and a consultant to iMDx, Nashville, Tennessee. He previously served as Lower Saxony Professor of Clinical Chemistry (2012–2017), Chairman of the Department of Clinical Chemistry/Central Laboratory (1991–2012), and Dean of the Faculty of Medicine.

An internationally recognized leader in therapeutic drug monitoring and precision diagnostics, Dr. Oellerich has advanced clinical implementation of cell-free DNA analytics, including cfDNA in oncology and donor-derived cfDNA in transplantation. His record includes more than 500 peer-reviewed publications, an H-index of 81, and over 21,986 citations.

Dr. Oellerich has held presidencies of multiple national and global organizations (IATDMCT, DGLM, DGKL, WASPaLM) and was Editor-in-Chief of Therapeutic Drug Monitoring (2003–2018), where he continues to serve as Associate Editor. His contributions have been recognized with numerous honors, including the Ludolf-Krehl Award, IATDMCT Charles Pippenger Award, WASPaLM Medal of Honor, WASPaLM Gold-Headed Cane, F. McCreary Prize (UBC Health, 2022), and the Claus Roxin Award (2023).
Prof. Robert J. Nash
PhytoQuest Limited, UK
Title: Iminosugars as novel anti-cancer and anti-inflammatory treatments
Robert started his research career working for the UK Medical Research Council on anti-HIV molecules from plants at the Royal Botanic Gardens Kew. His PhD was awarded by King’s College London on the identification and biological activities of new iminosugars. He was Head of the Chemistry Group at the BBSRC institute IGER from 1993-2002 and then founded 4 pharmaceutical discovery companies in the UK from 1999 to present. Currently Robert is director and researcher of PhytoQuest Limited and Sugars for Health Limited in the UK. The companies have several granted patent families around iminosugars and their potential drug uses. He has many collaborations with leading biologists and chemists in both universities and companies around the World and this is shown in the patents and publication record with over 250 refereed papers. He has a consistent track record within the pharma/biotech sector of building and leading successful R&D teams and has worked on many grant applications and project management teams. The R&D applications worked on have been broad across agri-food, pharmaceuticals, and cosmetics. The purpose of his research is to find better heath solutions involving better medicines or preventing disorders based mainly on manipulating carbohydrate biology. He is Honorary Professor at Swansea Department of Science and Technology.
Prof. Hang Fai Kwok
University of Macau, Macao
Title: AI-assisted modification of “venom-based peptide+dendrimer” nanoplatform for drug delivery
Hang Fai (Henry) Kwok is currently the Department Head and a Professor in the Faculty of Health Sciences at the University of Macau (UM). Before joining UM in 2014, he served as a Senior Research Fellow in the Department of Oncology at the Cancer Research UK Cambridge Institute at the University of Cambridge. His research focuses on proteins (antigens), venom-based peptides, and antibodies for targeted therapy and immunotherapy, with the aim of developing novel prototype drugs and treating cancer. In 2022, Henry was elected a Fellow of the Royal Society of Biology (FRSB) and a Fellow of the Royal Society of Chemistry (FRSC). In 2024 and 2025, he was included on the list of the World's Top 2% of Scientists.